Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2021 | Graft-Versus-Host Disease | Commentary

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

Authors: Amit Sharma, Ingo G. H. Schmidt-Wolf

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Abstract

Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.

Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–49. https://doi.org/10.1084/jem.174.1.139.CrossRefPubMed

Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol. 2020;235:9291–303. https://doi.org/10.1002/jcp.29827.CrossRefPubMed

Dalla Pietà A, et al. Innovative therapeutic strategy for B-cell malignancies that combines obinutuzumab and cytokine-induced killer cells. J Immunother Cancer. 2021;9. https://doi.org/10.1136/jitc-2021-002475.

Wang S, et al. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin Biol Ther. 2020;20:601–7. https://doi.org/10.1080/14712598.2020.1728250.CrossRefPubMed

Introna M, Correnti F. Innovative clinical perspectives for CIK cells in cancer patients. Int J Mol Sci. 2018;19. https://doi.org/10.3390/ijms19020358.

Wu X, Zhang Y, Li Y, Schmidt-Wolf IGH. Increase of Antitumoral effects of cytokine-induced killer cells by antibody-mediated inhibition of MICA shedding. Cancers (Basel). 2020;12. https://doi.org/10.3390/cancers12071818.

Gao X, et al. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Front Immunol. 2017;8:774. https://doi.org/10.3389/fimmu.2017.00774.CrossRefPubMedPubMedCentral

Stephan D, Weiher H, Schmidt-Wolf IGH. CIK cells and HDAC inhibitors in multiple myeloma. Int J Mol Sci. 2017;18. https://doi.org/10.3390/ijms18050945.

Liang S, et al. Cytokine-induced killer cells-assisted tumor-targeting delivery of Her-2 monoclonal antibody-conjugated gold nanostars with NIR photosensitizer for enhanced therapy of cancer. J Mater Chem B. 2020;8:8368–82. https://doi.org/10.1039/d0tb01391a.CrossRefPubMed

10.

Cappuzzello E, Sommaggio R, Zanovello P, Rosato A. Cytokines for the induction of antitumor effectors: the paradigm of cytokine-induced killer (CIK) cells. Cytokine Growth Factor Rev. 2017;36:99–105. https://doi.org/10.1016/j.cytogfr.2017.06.003.CrossRefPubMed

Title: 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective
Authors: Amit Sharma
Ingo G. H. Schmidt-Wolf
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Graft-Versus-Host Disease
Cytokines
Graft-Versus-Host Disease
Cancer Therapy
Cancer Immunotherapy
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-021-02184-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Correction to: ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma

Pyroptosis at the forefront of anticancer immunity

Cellular senescence or stemness: hypoxia flips the coin

Circular RNA circLMO7 acts as a microRNA-30a-3p sponge to promote gastric cancer progression via the WNT2/β-catenin pathway

The circular RNA circZFR phosphorylates Rb promoting cervical cancer progression by regulating the SSBP1/CDK2/cyclin E1 complex

Correction to: Downregulation of lncRNA ZNF582-AS1 due to DNA hypermethylation promotes clear cell renal cell carcinoma growth and metastasis by regulating the N(6)-methyladenosine modification of MT-RNR1

Keynote webinar | Spotlight on antibody–drug conjugates in cancer